Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Buy
51
GNTA Quote, Financials, Valuation and Earnings
Last price:
$4.13
Seasonality move
:
-0.83%
Day range:
$3.97 - $3.97
52-week range:
$2.20 - $7.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.03x
Volume:
269
Avg. volume:
34.4K
1-year change:
13.43%
Market cap:
$72.6M
Revenue:
--
EPS (TTM):
-$0.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNTA
Genenta Science SPA
|
-- | -- | -- | -- | -- |
|
DSRLF
Diasorin SpA
|
-- | -- | -- | -- | -- |
|
ELEAF
El.En. SpA
|
-- | -- | -- | -- | -- |
|
RICFY
Recordati SpA
|
-- | -- | -- | -- | -- |
|
SAFLF
Safilo Group SpA
|
-- | -- | -- | -- | -- |
|
STVN
Stevanato Group SpA
|
$294.9M | $0.12 | 5% | 29.39% | $26.84 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNTA
Genenta Science SPA
|
$3.97 | -- | $72.6M | -- | $0.00 | 0% | -- |
|
DSRLF
Diasorin SpA
|
$109.6000 | -- | $5.9B | 28.54x | $1.25 | 1.14% | 4.57x |
|
ELEAF
El.En. SpA
|
$9.80 | -- | $784.7M | 17.81x | $0.22 | 2.22% | 1.26x |
|
RICFY
Recordati SpA
|
$14.51 | -- | $12B | 26.88x | $0.16 | 2.26% | 4.79x |
|
SAFLF
Safilo Group SpA
|
$0.9500 | -- | $383.1M | 16.68x | $0.00 | 0% | 0.37x |
|
STVN
Stevanato Group SpA
|
$20.29 | $26.84 | $5.5B | 42.71x | $0.06 | 0.29% | 4.61x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNTA
Genenta Science SPA
|
-- | -0.046 | -- | -- |
|
DSRLF
Diasorin SpA
|
37.14% | -0.837 | -- | 1.67x |
|
ELEAF
El.En. SpA
|
10.22% | 0.000 | 6.2% | 1.76x |
|
RICFY
Recordati SpA
|
56.97% | 0.267 | 23.73% | 1.02x |
|
SAFLF
Safilo Group SpA
|
17.52% | -0.153 | 22.25% | 0.93x |
|
STVN
Stevanato Group SpA
|
22.69% | -0.033 | 7.21% | 1.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNTA
Genenta Science SPA
|
-- | -- | -- | -- | -- | -- |
|
DSRLF
Diasorin SpA
|
$206.8M | $69.3M | 9.02% | 10.8% | 21.95% | $217.9M |
|
ELEAF
El.En. SpA
|
$66.8M | $29.2M | 9.09% | 10.5% | 25.77% | $16.1M |
|
RICFY
Recordati SpA
|
$440.6M | $135.9M | 11.4% | 23.01% | 22.97% | -$763.6M |
|
SAFLF
Safilo Group SpA
|
-- | -- | 4.3% | 5.38% | -- | -- |
|
STVN
Stevanato Group SpA
|
$104.6M | $71.3M | 7.08% | 9.13% | 20.45% | $39.5M |
Genenta Science SPA vs. Competitors
-
Which has Higher Returns GNTA or DSRLF?
Diasorin SpA has a net margin of -- compared to Genenta Science SPA's net margin of 15.68%. Genenta Science SPA's return on equity of -- beat Diasorin SpA's return on equity of 10.8%.
Company Gross Margin Earnings Per Share Invested Capital GNTAGenenta Science SPA-- -- -- DSRLFDiasorin SpA65.51% $0.93 $2.8B -
What do Analysts Say About GNTA or DSRLF?
Genenta Science SPA has a consensus price target of --, signalling upside risk potential of 479.65%. On the other hand Diasorin SpA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genenta Science SPA has higher upside potential than Diasorin SpA, analysts believe Genenta Science SPA is more attractive than Diasorin SpA.
Company Buy Ratings Hold Ratings Sell Ratings GNTAGenenta Science SPA0 0 0 DSRLFDiasorin SpA0 0 0 -
Is GNTA or DSRLF More Risky?
Genenta Science SPA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Diasorin SpA has a beta of 0.178, suggesting its less volatile than the S&P 500 by 82.244%.
-
Which is a Better Dividend Stock GNTA or DSRLF?
Genenta Science SPA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Diasorin SpA offers a yield of 1.14% to investors and pays a quarterly dividend of $1.25 per share. Genenta Science SPA pays -- of its earnings as a dividend. Diasorin SpA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNTA or DSRLF?
Genenta Science SPA quarterly revenues are --, which are smaller than Diasorin SpA quarterly revenues of $315.6M. Genenta Science SPA's net income of -- is lower than Diasorin SpA's net income of $49.5M. Notably, Genenta Science SPA's price-to-earnings ratio is -- while Diasorin SpA's PE ratio is 28.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genenta Science SPA is -- versus 4.57x for Diasorin SpA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNTAGenenta Science SPA-- -- -- -- DSRLFDiasorin SpA4.57x 28.54x $315.6M $49.5M
-
Which has Higher Returns GNTA or ELEAF?
El.En. SpA has a net margin of -- compared to Genenta Science SPA's net margin of -2.06%. Genenta Science SPA's return on equity of -- beat El.En. SpA's return on equity of 10.5%.
Company Gross Margin Earnings Per Share Invested Capital GNTAGenenta Science SPA-- -- -- ELEAFEl.En. SpA58.85% -$0.03 $476.1M -
What do Analysts Say About GNTA or ELEAF?
Genenta Science SPA has a consensus price target of --, signalling upside risk potential of 479.65%. On the other hand El.En. SpA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genenta Science SPA has higher upside potential than El.En. SpA, analysts believe Genenta Science SPA is more attractive than El.En. SpA.
Company Buy Ratings Hold Ratings Sell Ratings GNTAGenenta Science SPA0 0 0 ELEAFEl.En. SpA0 0 0 -
Is GNTA or ELEAF More Risky?
Genenta Science SPA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison El.En. SpA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNTA or ELEAF?
Genenta Science SPA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. El.En. SpA offers a yield of 2.22% to investors and pays a quarterly dividend of $0.22 per share. Genenta Science SPA pays -- of its earnings as a dividend. El.En. SpA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNTA or ELEAF?
Genenta Science SPA quarterly revenues are --, which are smaller than El.En. SpA quarterly revenues of $113.5M. Genenta Science SPA's net income of -- is lower than El.En. SpA's net income of -$2.3M. Notably, Genenta Science SPA's price-to-earnings ratio is -- while El.En. SpA's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genenta Science SPA is -- versus 1.26x for El.En. SpA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNTAGenenta Science SPA-- -- -- -- ELEAFEl.En. SpA1.26x 17.81x $113.5M -$2.3M
-
Which has Higher Returns GNTA or RICFY?
Recordati SpA has a net margin of -- compared to Genenta Science SPA's net margin of 13.05%. Genenta Science SPA's return on equity of -- beat Recordati SpA's return on equity of 23.01%.
Company Gross Margin Earnings Per Share Invested Capital GNTAGenenta Science SPA-- -- -- RICFYRecordati SpA69.07% $0.10 $4.5B -
What do Analysts Say About GNTA or RICFY?
Genenta Science SPA has a consensus price target of --, signalling upside risk potential of 479.65%. On the other hand Recordati SpA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genenta Science SPA has higher upside potential than Recordati SpA, analysts believe Genenta Science SPA is more attractive than Recordati SpA.
Company Buy Ratings Hold Ratings Sell Ratings GNTAGenenta Science SPA0 0 0 RICFYRecordati SpA0 0 0 -
Is GNTA or RICFY More Risky?
Genenta Science SPA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recordati SpA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNTA or RICFY?
Genenta Science SPA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recordati SpA offers a yield of 2.26% to investors and pays a quarterly dividend of $0.16 per share. Genenta Science SPA pays -- of its earnings as a dividend. Recordati SpA pays out 60.92% of its earnings as a dividend. Recordati SpA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GNTA or RICFY?
Genenta Science SPA quarterly revenues are --, which are smaller than Recordati SpA quarterly revenues of $637.9M. Genenta Science SPA's net income of -- is lower than Recordati SpA's net income of $83.3M. Notably, Genenta Science SPA's price-to-earnings ratio is -- while Recordati SpA's PE ratio is 26.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genenta Science SPA is -- versus 4.79x for Recordati SpA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNTAGenenta Science SPA-- -- -- -- RICFYRecordati SpA4.79x 26.88x $637.9M $83.3M
-
Which has Higher Returns GNTA or SAFLF?
Safilo Group SpA has a net margin of -- compared to Genenta Science SPA's net margin of --. Genenta Science SPA's return on equity of -- beat Safilo Group SpA's return on equity of 5.38%.
Company Gross Margin Earnings Per Share Invested Capital GNTAGenenta Science SPA-- -- -- SAFLFSafilo Group SpA-- -- $536.1M -
What do Analysts Say About GNTA or SAFLF?
Genenta Science SPA has a consensus price target of --, signalling upside risk potential of 479.65%. On the other hand Safilo Group SpA has an analysts' consensus of -- which suggests that it could fall by --. Given that Genenta Science SPA has higher upside potential than Safilo Group SpA, analysts believe Genenta Science SPA is more attractive than Safilo Group SpA.
Company Buy Ratings Hold Ratings Sell Ratings GNTAGenenta Science SPA0 0 0 SAFLFSafilo Group SpA0 0 0 -
Is GNTA or SAFLF More Risky?
Genenta Science SPA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Safilo Group SpA has a beta of -69.335, suggesting its less volatile than the S&P 500 by 7033.488%.
-
Which is a Better Dividend Stock GNTA or SAFLF?
Genenta Science SPA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Safilo Group SpA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genenta Science SPA pays -- of its earnings as a dividend. Safilo Group SpA pays out 3.42% of its earnings as a dividend. Safilo Group SpA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GNTA or SAFLF?
Genenta Science SPA quarterly revenues are --, which are smaller than Safilo Group SpA quarterly revenues of --. Genenta Science SPA's net income of -- is lower than Safilo Group SpA's net income of --. Notably, Genenta Science SPA's price-to-earnings ratio is -- while Safilo Group SpA's PE ratio is 16.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genenta Science SPA is -- versus 0.37x for Safilo Group SpA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNTAGenenta Science SPA-- -- -- -- SAFLFSafilo Group SpA0.37x 16.68x -- --
-
Which has Higher Returns GNTA or STVN?
Stevanato Group SpA has a net margin of -- compared to Genenta Science SPA's net margin of 14.61%. Genenta Science SPA's return on equity of -- beat Stevanato Group SpA's return on equity of 9.13%.
Company Gross Margin Earnings Per Share Invested Capital GNTAGenenta Science SPA-- -- -- STVNStevanato Group SpA29.69% $0.19 $1.9B -
What do Analysts Say About GNTA or STVN?
Genenta Science SPA has a consensus price target of --, signalling upside risk potential of 479.65%. On the other hand Stevanato Group SpA has an analysts' consensus of $26.84 which suggests that it could grow by 32.29%. Given that Genenta Science SPA has higher upside potential than Stevanato Group SpA, analysts believe Genenta Science SPA is more attractive than Stevanato Group SpA.
Company Buy Ratings Hold Ratings Sell Ratings GNTAGenenta Science SPA0 0 0 STVNStevanato Group SpA5 3 0 -
Is GNTA or STVN More Risky?
Genenta Science SPA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stevanato Group SpA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNTA or STVN?
Genenta Science SPA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stevanato Group SpA offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. Genenta Science SPA pays -- of its earnings as a dividend. Stevanato Group SpA pays out 12.28% of its earnings as a dividend. Stevanato Group SpA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GNTA or STVN?
Genenta Science SPA quarterly revenues are --, which are smaller than Stevanato Group SpA quarterly revenues of $352.4M. Genenta Science SPA's net income of -- is lower than Stevanato Group SpA's net income of $51.5M. Notably, Genenta Science SPA's price-to-earnings ratio is -- while Stevanato Group SpA's PE ratio is 42.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genenta Science SPA is -- versus 4.61x for Stevanato Group SpA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNTAGenenta Science SPA-- -- -- -- STVNStevanato Group SpA4.61x 42.71x $352.4M $51.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
